Health Canada Grants No Objection Letter to Epygenix Therapeutics to Proceed With ARGUS Trial for the Treatment of Dravet Syndrome

PARAMUS, N.J., Aug. 2, 2021 /PRNewswire/ -- Epygenix Therapeutics, Inc., a clinical stage biopharmaceutical company focused on rare and intractable genetic epilepsy, is pleased to announce that the company's ARGUS trial with EPX-100 (Clemizole Hydrochloride) in patients with Dravet...

from PR Newswire: https://ift.tt/37bPH4W